Oct 13 (Reuters) - Johnson & Johnson reported a 1.7% rise in third-quarter sales on Tuesday due to higher demand for its cancer drugs, a day after the company said it had paused its COVID-19 vaccine trials.
The healthcare conglomerate late Monday said it had temporarily paused its COVID-19 vaccine candidate clinical trials due to an unexplained illness in a study participant, delaying one of the highest profile efforts to contain the global pandemic.
Quarterly sales rose to $21.08 billion from $20.73 billion. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
Our Standards: The Thomson Reuters Trust Principles.